Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304873 · ClinicalTrials.gov registry record · Phase 3
Retapamulin as a Decolonizing Agent for MRSA
A Phase 3 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
NCT03304873 is a Phase 3 study that has completed, run by NYU Langone Health. The registered enrollment target is 47 participants.
The verdict
NCT03304873, a Phase 3 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of retapamulin to reduce carriage of MRSA via a randomized, double-blind, placebo-controlled clinical study testing retapamulin among patients with confirmed mupirocin-resistant nasal and/or rectal MRSA colonization. The sample size will include 27 subjects in each of the two arms of the study (retapamulin versus placebo) for a total of 54 subjects. Participants who are found to be nasal and/or rectal colonized with MRSA will be randomized to receive either retapamulin or placebo applied nasally and rectally for a total of 5 days. Nasal and rectal swabs will be collected at pre-defined time points during study duration (screening swab, swab one week after completion of topical therapy, swab 4 weeks after completion of topical therapy) to assess MRSA colonization status. The colonization rates of both groups will be assessed via Fisher's Exact Test.
Interventions
- DRUG Retapamulin
- DRUG Placebo Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03304873
The ClinicalTrials.gov registry entry for NCT03304873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Retapamulin is the first listed.
NCT03304873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03304873 about?
NCT03304873 is a clinical study titled "Retapamulin as a Decolonizing Agent for MRSA". The purpose of this study is to investigate the efficacy of retapamulin to reduce carriage of MRSA via a randomized, double-blind, placebo-controlled clinical study testing retapamulin among patients with confirmed mupirocin-resistant nasal and/or rectal MRSA colonization. The sample size will inclu...
What is the current status of trial NCT03304873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2017-12-01. Estimated completion is 2019-03-18.
What interventions are being tested in trial NCT03304873?
The interventions under investigation include: Retapamulin (DRUG), Placebo Ointment (DRUG).
Who is sponsoring clinical trial NCT03304873?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.